GLAXOSMITHKLINE PHARMACEUTICALS LTD. Q2 FY26 Results
GLAXOQ2 FY26 ResultsAnnounced 6 Nov 2025, 04:19 pm| Metric | Value (₹ Cr) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 979.94 | 21.7% | 3.0% |
| Total Income | 1.0K | 19.4% | 3.0% |
| Expenditure | 662.15 | 16.2% | 6.2% |
| PBT | 354.00 | 26.9% | 3.0% |
| Net Profit | 257.49 | 25.6% | 2.0% |
| OPM | 34.53% | 3.33pp | 5.63pp |
| NPM | 25.41% | 1.26pp | 1.25pp |
| EPS | 15.07 | 24.6% | 2.7% |
GSK India's Q2FY26 Performance: EBIDTA Margin Grows By 250 Basis Points, Oncology Portfolio Off to a Strong Start
06 Nov 2025 · 6 Nov 2025, 04:51 pm
Summary
GlaxoSmithKline Pharmaceuticals Ltd (GSK India) announced its Q2FY26 results with EBIDTA margin growing by 250 basis points, driven by improved gross margins and operating leverage. The company saw muted topline growth due to temporary challenges, but demonstrated strong profitability. The General Medicines portfolio delivered competitive performance and the Vaccines business saw market share expansion. GSK's entry into Oncology with the launch of Jemperli and Zejula has been well-received.
Key Highlights
- 1
Revenue from Operations was INR 974 Crores
- 2
Profit After Tax (PAT) was INR 255 Crores
- 3
EBIDTA margins for the quarter stood at 34.4%
- 4
General Medicines portfolio delivered competitive performance
- 5
Vaccines business saw market share expansion
- 6
GSK's Oncology portfolio launched with Jemperli and Zejula
Management Comments
Bhushan Akshikar
Managing Director, GSK India
Within two months of launch, our Oncology portfolio is impacting patients by addressing a critical unmet need in gynaecological cancers in India. Together, these assets represent meaningful progress in women’s cancer care.
Informational and educational content only. Not investment advice.